<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170920</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-IUSCC-0715</org_study_id>
    <nct_id>NCT04170920</nct_id>
  </id_info>
  <brief_title>Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs</brief_title>
  <official_title>Pilot Study of a Mobile Health Strategy to Improve Medication Adherence in Breast Cancer Survivors Receiving Aromatase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of an mobile-health strategy to
      improve patient-reported symptoms, promote life-saving medication adherence, and encourage
      healthy lifestyle behaviors in early stage breast cancer survivors receiving adjuvant
      Aromatase inhibitors, while beginning to predict psycho-social and demographic
      characteristics of those who benefit most from this approach. This will provide preliminary
      experience and evidence for larger, randomized clinical trials evaluating this methodology,
      which will have immediate and scalable influence on cancer survivor ship.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, prospective, observational study enrolling up to 50 patients to the
      intervention in groups of 10 within Indiana University Simon Cancer Center. Subjects must
      meet eligibility at the time of informed consent. Once 10 eligible subjects are identified
      and have signed informed consent, each subject will return for their baseline visit and begin
      the app intervention with their group of 10.

      Primary Objective Evaluate the feasibility of a smartphone application, LifeExtend-AI, in
      patients with early stage breast cancer currently prescribed aromatase inhibitor therapy,
      determined by patient usage of the application.

      Secondary Objectives

        1. Determine a preliminary estimate of effect size of the app intervention on medication
           adherence, by self- report questionnaire MMAS-4.

        2. Determine a preliminary estimate of effect size of the app intervention on patient
           -reported AI arthralgia, as measured by the Basic Pain Inventory (BPI).

        3. Determine a preliminary estimate of effect size of the app intervention on patient
           reported health associated quality of life, measured by the Functional Assessment of
           Cancer Therapy- Endocrine symptoms (FACT-ES) questionnaire.

        4. Determine a preliminary estimate of the effect size of the app intervention on patient
           satisfaction with healthcare team communication, measured by the FACIT- Treatment
           Satisfaction-Patient Satisfaction questionnaire (FACIT-TS-PS).

        5. Determine a preliminary estimate of effect size of the app intervention on patient
           reported health depression and anxiety, as measured by the Hospital Anxiety and
           Depression Scale (HADS).

        6. Determine a preliminary estimate of effect size of the app intervention on patient
           reported physical activity level, as measured by the International Physical Activity
           Questionnaire (IPAQ).

        7. Investigate psychosocial and behavioral determinants of application usage and subsequent
           medication adherence, including perceived AI necessity, fear of cancer recurrence,
           health self-efficacy, and e-health literacy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants who use the LifeExtend-AI application 5 or more days per week</measure>
    <time_frame>12 weeks</time_frame>
    <description>Feasibility will be measured by participants who use the application 5 or more days per week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean medication adherence using the Adapted Morisky Medication Adherence Scale (MMAS-4)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>A self report 5 question scale where a total score of 0 indicates high adherence; a score of 1 or 2 indicates intermediate adherence; and a score of 3 or 4 indicates low adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain score of self -reported aromatase inhibitor arthralgia using the Basic Pain Inventory (BPI)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>Mean score of the 9 item scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean quality of life score, measured by the Functional Assessment of Cancer Therapy- Endocrine symptoms (FACT-ES)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>Likert-scaled questionnaire, with response scores ranging from 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean satisfaction with healthcare team communication, measured by the FACIT- Treatment Satisfaction-Patient Satisfaction questionnaire (FACIT-TS-PS)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>Likert-scaled questionnaire, with response scores ranging from 0 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean quality of life, as measured by the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The HADS uses a scale and therefore the data returned from the HADS is ordinal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean quality of life, as measured by the International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>MET-min per week: MET level x minutes of activity x events per week. To calculate MET minutes a week multiply the MET value given by the minutes the activity was carried out and again by the number of days that that activity was undertaken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean quality of life, as measured by the eHEALTH literacy scale (ehEALS)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>he eHEALS contains 8 items, measured with a 5-point Likert scale with response options ranging from &quot;strongly disagree&quot; to &quot;strongly agree.&quot; Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean quality of life, as measured by the Patient Activation Measure (PAM)</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>A 13-item survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or herown health and healthcare on a 100 point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean quality of life, as measured by the assessment of cancer worry in aromatase inhibitor users</measure>
    <time_frame>Baseline and post intervention (an average of 12 weeks)</time_frame>
    <description>Mean score of 3 item scale with responses on a 1-10 scale where 0 indicates &quot;not at all&quot; and 10 indicates &quot;a great deal&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>Mobile Health Application Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating &quot;to-do&quot; lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifeExtend-AI</intervention_name>
    <description>LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating &quot;to-do&quot; lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added.</description>
    <arm_group_label>Mobile Health Application Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. â‰¥ 18 years old at the time of informed consent

          2. Regular access to a smartphone capable of downloading the application

               1. iOS 11 or later (iPhone5, iPhone SE or newer)

               2. Android 6 or later (Android 9 is current version)

          3. History of DCIS, stage I, II, or III invasive breast cancer

          4. Currently prescribed an aromatase inhibitor (letrozole, anastrozole, exemestane) or
             planned to be initiated on one by the time of signing informed consent. Patient
             already on an AI must have been prescribed this medication for a total of 36 months or
             less.

               1. Ovarian suppression with AI is allowed in premenopausal patients.

               2. Prior SERM and now switching to an AI for the first time is allowed.

               3. Concurrent trastuzumab, pertuzumab, or TDM1 is allowed.

               4. Concurrent neratinib or other oral cancer directed medication is not allowed.

          5. ECOG performance status of 0-2

        Exclusion Criteria:

          1. Metastatic breast cancer or other active malignancy

               1. Locally recurrent breast cancer is allowed if treated with surgical excision and
                  AI is prescribed with curative intent.

               2. History of prior treated malignancies, other than breast cancer, that are now
                  stable, are in remission, and do not require active therapy, are acceptable

          2. Unable to read the English language or otherwise participate in the study procedures
             in the opinion of the treating investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarah Ballinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Millicent MacGregor, RN</last_name>
    <phone>317-274-5288</phone>
    <email>milmacgr@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarah Ballinger, MD</last_name>
    <email>tarab@iu.edu</email>
  </overall_contact_backup>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Tarah J Ballinger, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>DCIS</keyword>
  <keyword>aromatase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

